Biomedicines · Nov 19, 2026

Cardiovascular Medications as Disease Modifiers for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Literature Review

By Robaeys W, Koek GH, Penders J et al.

Background/Objectives: It is suggested that medications treating cardiovascular disease may influence the evolution of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its complications. Methods: A literature review in PubMed regarding the outcomes of these medications was conducted, primarily focusing on studies including liver histology, if available. Histology remains the best standard for proof of efficacy. Also, the mechanism of action, in particular, at the level of the liver sinusoids, was reviewed. Results: According to histology-based randomized controlled trials and/or meta-analyses, there is coherent evidence, in MASLD patients, that statins are beneficial for Metabolic Dysfunction-Associated Steatotic Hepatitis (MASH) (evidence level (E) 2, recommendation (R) strong), for fibrosis (E 2, R intermediate) and for hepatocellular carcinoma (HCC) (E 2, R strong)) and, hence, can be recommended to be prescribed within their label in MASLD patients. Also, aspirins and angiotensin II receptor 1 blockers have well-documented benefits regarding MASH (both E 2, R weak), fibrosis (both E 2, R weak) and HCC (resp E 2, R Intermediate; E 3, R weak). Further prospective cohort studies should be performed for aspirins, ACEi and ARB in MASLD patients to assess their impact on outcomes. This modification in MASLD and its complications is mainly caused by interference at the level of the liver sinusoids within the liver sinusoidal lining endothelial cell–stellate cell axis. Conclusions: Based on histological studies and/or meta-analysis, cardiovascular medications modify the progression of MASLD and its complications. Further prospective cohort studies should be performed.

doi.org/10.3390/biomedicines14112687Interventions

AgingResearch.News